Results Obtained at Sunnybrook With ART's Softscan Breast Imaging System Presented at IEEE International Conference
September 04 2009 - 10:54AM
Marketwired
ART Advanced Research Technologies Inc. (ART) (TSX: ARA), a
Canadian medical device company and a leader in optical molecular
imaging products for the healthcare and pharmaceutical industries,
is pleased to announce that Dr. Gregory Czarnota, MD, PhD,
Radiation Oncologist at Odette Cancer Centre, Sunnybrook Health
Sciences Centre, will be presenting SoftScan® clinical results from
a breast cancer treatment monitoring study, at the IEEE Engineering
in Medicine and Biology Society 31st Annual International
Conference in Minneapolis, Minn. The study to determine the
efficacy of the SoftScan system in monitoring response to treatment
of breast cancer, particularly neoadjuvant therapies, was conducted
at the Sunnybrook Health Sciences Centre, among North America's
most important cancer centres, with Dr. Czarnota as the principal
investigator.
Mr. Sebastien Gignac, ART's Chairman & CEO said: "These
findings further validate the powerful role of the SoftScan optical
imaging system in breast cancer research, and for treatment
monitoring in particular. There is a pressing need to develop
better, more personalized, treatments regimens for breast cancer
patients in order to diminish unnecessary suffering as well as to
better control escalating chemotherapy costs for the health sector,
and we believe that SoftScan can play a useful role in this regard,
as the study led by Dr. Czarnota indicates."
Dr. Gregory Czarnota, also Scientist, Sunnybrook Research
Institute, who led the study, stated: "Results from the study
confirm that 50% to 70% of women with locally advanced breast
cancer are not responding well to initial chemotherapy, which
suggests there is a strong unmet need for early evaluation in
treatment monitoring. Our findings may make it easier and more cost
efficient for researchers to develop effective treatments for
breast cancer, because SoftScan can characterize tumour responses
by their metabolic signatures. I have high hopes for SoftScan
because it offers what conventional modalities do not and can
potentially lead to better outcomes." Study results have been
submitted for publication in a peer-reviewed oncology journal.
With other existing imaging modalities, clinicians must
conventionally wait for weeks before being able to determine
response to treatment. Consequently, clinicians have had difficulty
knowing in a timely fashion if the treatment was having an effect.
Aided by the SoftScan imaging system, clinicians are able to
non-invasively assess the spread and growth of the tumors in the
breast between one and four weeks of starting the treatment
regimen. This provides doctors with additional insight into how
effective a potential drug or treatment may be and as to whether or
not the patient should be switched to a different regimen.
Dr. Gregory Czarnota will be presenting highlights from the
study in a session entitled "Recent Advances in Novel Optical
Imaging Technologies" on Friday, September 4 at 14:45 CT in the
Marquette VII hall of the Hilton Minneapolis. The abstract is
available at the following link:
https://embs.papercept.net/conferences/scripts/abstract.pl?ConfID=9&Number=1710.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix® optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is used by industry and academic leaders worldwide. The
SoftScan® optical medical imaging device is designed to improve the
diagnosis and treatment of breast cancer. Finally, the Fenestra®
line of molecular imaging contrast products provides image
enhancement for a wide range of preclinical Micro CT applications
allowing scientists to see greater detail in their imaging studies,
with potential extension into other major imaging modalities. ART
is commercializing some of these products in a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at
www.art.ca.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2008, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024